利培酮口服液与喹硫平治疗精神分裂症的对照研究  

Control study of Risperidone Oral Solution and quetiapine on schizophrenia

作　　者：宋光明[1] 李建华[1] 钟华[1] 卢胜利[1] 

机构地区：[1]浙江省湖州市第三人民医院,浙江湖州313000

出　　处：《现代中西医结合杂志》2008年第32期4961-4963,共3页Modern Journal of Integrated Traditional Chinese and Western Medicine

摘　　要：目的探讨利培酮口服液治疗精神分裂症的疗效及安全性。方法将66例精神分裂症患者随机分为利培酮口服液组(32例)和喹硫平组(34例),治疗2个月再随访3个月(共5个月)。在治疗前及治疗1,2个月末和随访结束时使用阳性与阴性症状量表(PANSS)、治疗中出现的症状量表(TESS)评定疗效及不良反应,并于治疗前、中、后检测催乳素水平;用世界卫生组织生存质量测定量表(WHOQOL-BREF)在治疗前及随访结束时评估患者的生存质量。结果随访结束时,利培酮口服液组显效率66%,有效率88%;喹硫平组显效率59%,有效率82%。2组疗效无显著性差异(P>0.05)。2组PANSS总分和各因子分均较治疗前明显下降(P<0.01),而2组间比较无显著性差异(P>0.05)。不良反应总的发生率2组间无显著性差异(P>0.05)。利培酮口服液组催乳素水平明显升高,喹硫平组则无影响,2组间比较有显著性差异(P<0.01)。2组生存质量各指标均较治疗前显著改善(P<0.01),但2组间比较无显著性差异(P>0.05)。结论利培酮口服液治疗精神分裂症有效、安全、起效快。Objective It is to discuss the curative effect and safety of Risperidone Oral Solution on schizophrenia. Methods 66 patients with schizophrenia were randomly divided to Risperidone Oral Solution group （ n = 32） and quetiapine group （ n = 34 ）. The two groups were treated for two months and followed up for three months. The curative effects and untoward reaction were assessed with positive and negative syndrome scale （PANSS） and treatment emergent symptom scale （TESS） before treatment, at the ends of the first and second month after treatment and at the end of follow up. The Prolaetin level was detected before, during and after treatment. The life qualities of the patients were assessed with WHOQOL - BREF before treatment and at the end of follow up. Results At the end of follow up, the excellence rate and effective rate in Risperidone Oral Solution group were 66 % and 88 %, and those in quetiapine group were 59 % and 82 %, there was no significant difference （P 〉 0.05 ）. Both the total PANSS scores and various factor scores in the two groups lowered obviously compared with before treatment （ P 〈 0.01）, but there was no significant difference between the two groups （ P 〉 0.05）. There was no sig- nificant difference on the total incidence rate of untoward reaction between the two groups （P 〉 0.05 ）. The Prolactin level in Risperidone Oral Solution group heightened obviously, but that in quetiapine group had no changes, there was significant difference between the two groups （P 〈 0.01 ）. The various indexes of life qualities in the two groups improved significantly compared with before treatment （P 〈0.01）, but there was no significant difference between the two groups （P〉0.05）. Conclusion Risperidone Oral Solution on schizophrenia is effective, safe and rapid action.

关 键 词：利培酮口服液 喹硫平 精神分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]